mgi-114 Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1
  • InChIKey: NICJCIQSJJKZAH-AWEZNQCLSA-N
  • Mol. Mass: 246.31
  • ALogP: 1.67
  • ChEMBL Molecule:
    irofulven  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

6-hydroxymethylacylfulvene | 6-(hydroxymethyl)acylfulvene | hmaf | hmaf cpd | irofulven | (-)-irofulven | mgi 114 | mgi-114 | mgi.114

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Hamartoma (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 1)

Liver Neoplasms (Phase 1/Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Thyroid Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue